Home
PSTV
PSTV News

Latest PLUS THERAPEUTICS Inc. (PSTV) News on September 16, 2025

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire

13 days ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

GlobeNewswire

3 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

GlobeNewswire

3 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

MT Newswires

3 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

3 months ago

Top Midday Gainers

MT Newswires

3 months ago

Plus Therapeutics Says FDA Clears Reyobiq IND Application for Pediatric Brain Cancer; Shares Up Pre-Bell

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

GlobeNewswire

3 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

GlobeNewswire

3 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Plus (PSTV) Upgraded to Buy: Here's Why

Zacks

3 months ago

Plus (PSTV) Upgraded to Buy: Here's Why

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

GlobeNewswire

4 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates

Zacks

4 months ago

The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

GlobeNewswire

4 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks

4 months ago

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

GlobeNewswire

4 months ago

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Zacks

4 months ago

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

GlobeNewswire

4 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Zacks

5 months ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Zacks

5 months ago

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

GlobeNewswire

5 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

GlobeNewswire

5 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Zacks

5 months ago

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Plus Therapeutics Inc Earnings Call

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

6 months ago

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Zacks

6 months ago

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire

6 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Zacks

6 months ago

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

Insider Monkey

6 months ago

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

MT Newswires

6 months ago

Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

GlobeNewswire

6 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

GlobeNewswire

6 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

ACCESS Newswire

6 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

GlobeNewswire

6 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

Insider Monkey

6 months ago

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Zacks

6 months ago

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

MT Newswires

6 months ago

Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

Pharmaceutical Technology

6 months ago

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

MT Newswires

6 months ago

Top Premarket Gainers

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

GlobeNewswire

6 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

MT Newswires

6 months ago

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

GlobeNewswire

6 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire

6 months ago

Plus Therapeutics Announces New Employment Inducement Grants

MT Newswires

6 months ago

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

GlobeNewswire

6 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

GlobeNewswire

7 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

GlobeNewswire

7 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

GlobeNewswire

7 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

GlobeNewswire

7 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

9 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/10/2024

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/09/2024

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/06/2024

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/05/2024

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

9 months ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/04/2024

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

GlobeNewswire

9 months ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

Medical Device Network

10 months ago

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

GlobeNewswire

10 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

GlobeNewswire

10 months ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/22/2024

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

GlobeNewswire

10 months ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/21/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/20/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/19/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/18/2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

10 months ago

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/15/2024

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

10 months ago

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

10 months ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/14/2024

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/13/2024

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

Zacks

10 months ago

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/08/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/07/2024

MT Newswires

10 months ago

Plus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

GlobeNewswire

10 months ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/06/2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

GlobeNewswire

10 months ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/05/2024

Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates

Zacks

10 months ago

Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/04/2024

MT Newswires

10 months ago

Plus Therapeutics Gets Additional Time to Regain Compliance With Nasdaq Listing Requirement

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/31/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/30/2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

GlobeNewswire

a year ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/29/2024

Share on Social Networks: